Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

117results about How to "Inhibiting and reducing" patented technology

Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
Owner:LUMENA PHARMA INC

Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors

ActiveUS20130344061A1Relieve symptomsPrevents mast cell degranulationBiocideOrganic chemistryDiseaseInflammatory myopathy
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
Owner:INFINITY PHARMA

Breast implant implantation method and apparatus

InactiveUS20110082546A1Inhibit and reduce formation of scar tissueInhibiting and reducingMammary implantsDiagnosticsAseptic processingDilator
A method for implanting a breast implant into a subject, the method includes: providing a sterile, flexible, elastic biodegradable bag sized to contain the breast implant; providing a sterile breast implant; inserting, using sterile handling, the sterile breast implant into the sterile bag to form a sterile breast implant assembly; closing the bag to fully enclose the implant within the bag; and implanting in a sterile manner the sterile breast implant assembly into the subject. A sterile bag, which may be provided in a kit, preferably for use with the method includes first and second chambers connected by a channel for moving a breast implant from the first chamber through the channel to the second chamber without directly touching the implant. An incision dilator may also be included with the kit or separately provided for use in a preferred embodiment of the method.
Owner:BREAST SHIELD MATERIALS

Antibody/drug conjugates and methods of use

ActiveUS20140127241A1Reducing and inhibiting proliferationReducing and inhibiting and growthAntibacterial agentsAntimycoticsDiseaseDrug conjugation
The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
Owner:A28 THERAPEUTICS INC

Prevention and treatment of cerebral amyloid angiopathy

InactiveUS20080292625A1Reduces and inhibits vascular amyloidogenic pathologyMinimizes microhemorrhageNervous disorderImmunoglobulins against animals/humansAmyloid angiopathyDisease cause
The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1

Glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS

Prevention and treatment of cerebral amyloid angiopathy

InactiveUS20090142270A1Reduces and inhibits development of vascularMinimizes microhemorrhageNervous disorderImmunoglobulins against animals/humansAmyloid angiopathyAntibody
The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody.
Owner:JANSSEN SCI IRELAND UC +1

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.
Owner:HEALTH & HUMAN SERVICES THE GOVERNMENT OF THE US SEC THE DEPT OF

IGF-binding protein-derived peptide or small molecule

InactiveUS6914049B2Reducing tumor invasivenessReducing and inhibiting vascular restenosisSenses disorderNervous disorderPeptideSmall molecule
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.
Owner:BIOEXPERTISE +1

Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof

Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.
Owner:MT SINAI SCHOOL OF MEDICINE

Acylated glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS

Oral immunotherapy of bacterial overgrowth

The object of the present invention is the oral administration of animal immunoglobulins for the treatment of gastrointestinal disorders caused by bacterial and / or yeast overgrowth. Immunoglobulins derived from the blood, plasma or serum of animals, such as cow, goats, sheep and pigs, contain a broad spectrum of antibodies to bacteria and yeast that afflict the gastrointestinal tract of human patients.
Owner:BIER MILAN

IGF-binding protein-derived peptide

InactiveUS6887851B2Reducing tumor invasivenessReducing and inhibiting vascular restenosisBiocidePeptide/protein ingredientsSmall moleculePeptide
New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.
Owner:ENMODULIN INC +1

Glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS

Glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS

Combination therapy for the treatment of influenza

InactiveUS20090298797A1Increase survivabilityInhibiting or reduceBiocideSalicyclic acid active ingredientsNeuraminidase inhibitorInflammation
Compositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection compared to administration of the neuraminidase inhibitor alone. A preferred neuraminidase inhibitor is zanamivir. Preferred immunomodulators include, but are not limited to celecoxib and mesalazine. Another embodiment provides a method for treating influenza, preferably, influenza due to infection with avian influenza A (H5N1) by administering to subject infected with the influenza virus, an effective amount of a neuraminidase inhibitor to inhibit or reduce budding of the influenza virus from infected cells of the subject, and an effective amount of at least two immunomodulators effective to reduce or inhibit one or more symptoms of inflammation in the subject.
Owner:BRIDGESTONE CORP +1

Redox flow battery and method for operating the battery continuously in a long period of time

The present invention provides a redox flow battery comprising a positive electrolyte storage tank and a negative electrolyte storage tank, wherein the positive electrolyte storage tank and the negative electrolyte storage tank is kept to be in liquid communication through a pipe, wherein the length-to-diameter ratio of the pipe for the liquid communication is not less than about 10. The present invention also provides a method for operating the redox flow battery continuously in a long period of time.
Owner:BEIJING PRUDENT CENTURY TECH CO LTD

Breast implant implantation method and apparatus

A method for implanting a breast implant into a subject, the method includes: providing a sterile, flexible, elastic biodegradable bag sized to contain the breast implant; providing a sterile breast implant; inserting, using sterile handling, the sterile breast implant into the sterile bag to form a sterile breast implant assembly; closing the bag to fully enclose the implant within the bag; and implanting in a sterile manner the sterile breast implant assembly into the subject. A sterile bag, which may be provided in a kit, preferably for use with the method includes first and second chambers connected by a channel for moving a breast implant from the first chamber through the channel to the second chamber without directly touching the implant. An incision dilator may also be included with the kit or separately provided for use in a preferred embodiment of the method.
Owner:BREAST SHIELD MATERIALS

Influenza virus vaccines and uses thereof

ActiveUS20140328875A1Highly potent and broadly neutralizing antibodiesStimulate immune responseSsRNA viruses negative-senseBacteriaHemagglutininInfluenza virus vaccine
Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
Owner:MT SINAI SCHOOL OF MEDICINE

Lytic domain fusion constructs and methods of making and using same

ActiveUS20090269341A1Reducing and inhibiting and growthReducing and inhibiting proliferationNervous disorderFollicle-stimulating hormoneAbnormal tissue growthAberrant cell
The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.
Owner:A28 THERAPEUTICS INC +1

Methods for detecting and inhibiting angiogenesis

InactiveUS7056506B2Reducing and inhibiting angiogenesisReduce severityBiocidePeptide/protein ingredientsΑ5β1 integrinAngiogenesis growth factor
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.
Owner:RGT UNIV OF CALIFORNIA

Influenza virus vaccines and uses thereof

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.
Owner:MT SINAI SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products